Palomar Q1 Beats and Raises, but Key Tests Remain Ahead

What happened

Palomar Holdings reported a strong Q1 2026, with management highlighting broad-based premium growth, continued underwriting profitability, and an increased full-year adjusted net income outlook. The earnings call reinforced the narrative of sustained outperformance, but the underlying guidance signals a normalization from 2025 levels, with a loss ratio expected to rise to the mid-to-upper 30s. While the market reacted positively, the stock at ~$160 already prices in a soft landing from the current high profitability. The next critical test comes with the June 1 reinsurance renewal and the first reported surety segment results under the new Palomar Casualty & Surety Company. Until these milestones provide clear evidence that underwriting discipline holds through the mix shift and that the new covenant-bearing capital structure remains comfortable, the risk/reward remains balanced.

Implication

The Q1 beat and raised guidance confirm Palomar's operational strength, but the investment case hinges on execution of the Gray Surety integration and the reinsurance renewal. The new $450M facility adds covenant sensitivity that becomes binding if underwriting weakens. Investors should wait for the 6/1 reinsurance renewal and Q2 surety loss data before committing new capital. The attractive entry point around $105 remains the target for a meaningful position.

Thesis delta

The strong Q1 results, while positive, do not alter the wait thesis because the key uncertainties around reinsurance economics, surety loss emergence, and the impact of the new leverage structure remain unresolved. The increased guidance is already priced into the stock at ~$160, leaving limited upside without confirmation of sustained underwriting discipline. The thesis shifts only if the June reinsurance renewal and early surety results clearly de-risk the outlook, or if a pullback to the $105 entry offers a better margin of safety.